Alyeska Investment Group
SNNA

Alyeska Investment Group’s Sienna Biopharmaceuticals, Inc. SNNA Stock Holding History

Alyeska Investment Group’s Portfolio SNNA Stock Details SNNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-27,730
Closed -$421K – 565
2018
Q2 		$421K Sell
27,730
-22,724
-45% -$386K ﹤0.01% 428
2018
Q1 		$948K Sell
50,454
-455
-0.9% -$7.95K 0.01% 392
2017
Q4 		$924K Hold
50,909
– – 0.01% 386
2017
Q3 		$1.13M Buy
+50,909
New +$1.12M 0.01% 411

Other funds holding SNNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return
CCP
Clough Capital Partners Boston, Massachusetts $1.04B AUM 49.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Alyeska Investment Group's SNNA Position: Q3 2018 in Review

Alyeska Investment Group sold out of Sienna Biopharmaceuticals, Inc. (SNNA) in Q3 2018, closing a stake of 27,730 shares — an estimated $421K sold.

Alyeska Investment Group first reported a position in SNNA in Q3 2017 and held it in 4 quarters. The position peaked at $1.13M in Q3 2017. 54 funds tracked by Wall St. Rank hold SNNA as of Q3 2018.

  • Alyeska Investment Group reported no remaining Sienna Biopharmaceuticals, Inc. position as of Q3 2018 after selling out during the quarter.
  • Alyeska Investment Group sold 27,730 Sienna Biopharmaceuticals, Inc. shares in Q3 2018, an estimated $421K.
  • Alyeska Investment Group first reported a position in Sienna Biopharmaceuticals, Inc. in Q3 2017 and held it in 4 quarters.
  • Alyeska Investment Group's Sienna Biopharmaceuticals, Inc. position peaked at $1.13M in Q3 2017.
  • 54 funds tracked by Wall St. Rank held Sienna Biopharmaceuticals, Inc. as of Q3 2018.

Based on Alyeska Investment Group's 13F filing for Q3 2018, filed 14 Nov 2018.